Investigation Alert Baxter International, Eagle Pharmaceuticals, BioXcel Therapeutics, and ImmunityBio: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP, investigates potential violations of federal and state laws by certain officers of the companies of Baxter International, Inc. (NYSE: BAX), Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX), BioXcel Therapeutics, Inc. (NASDAQ: BTAI), and ImmunityBio, Inc. (NASDAQ: IBRX).*Baxter International, Inc. (NYSE: BAX)*
Johnson Fistel, LLP is investigating potential claims on behalf of Baxter International, Inc. (NYSE: BAX).
If you are a current, long-term shareholder of Baxter International, continuously holding your shares since May 25, 2022, you may have standing to hold the company harmless from the alleged harm caused by the Company's officers and directors by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing. You can click or copy and paste the link below in a browser to join this action:
*https://www.johnsonfistel.com/investigations/baxter-international*
Recently a class action lawsuit was filed against Baxter International. According to the complaint, during the class period, defendants materially misrepresented and/or concealed the true nature and severity of supply chain problems it was encountering and the impact they were having on the Company’s current and expected earnings. Defendants’ failure to disclose Baxter’s true problems relating to its supply chain deceived investors about the Company’s true financial health and earnings.
*Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX)*
Johnson Fistel, LLP is investigating potential claims on behalf of Eagle Pharmaceuticals, Inc. against certain of its officers and directors.
If you are a current, long-term shareholder of Aug. 8, 2023, continuously holding your shares since April 21, 2022, you may have standing to hold the company harmless from the alleged harm caused by the Company's officers and directors by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing. You can click or copy and paste the link below in a browser to join this action:
https://www.cognitoforms.com/JohnsonFistel/EaglePharmaceuticalsInc
Recently a class action complaint was filed against the company. The securities class action lawsuit alleges that Defendants misrepresented and failed to disclose that: (i) Eagle Pharmaceuticals was experiencing slower than anticipated pull-though from a wholesale customer predominantly due to expiry of inventory; (ii) as a result, Eagle Pharmaceuticals had overstated its revenue; and (iii) Eagle Pharmaceuticals did not have effective internal controls and procedures over financial reporting as to sales for its lung cancer drug PEMFEXY.
*BioXcel Therapeutics, Inc. (NASDAQ: BTAI)*
Johnson Fistel, LLP is investigating potential claims on behalf of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) against certain of its officers and directors.
If you are a current, long-term shareholder of Bioxcel, continuously holdings shares since December 15, 2021, you may have standing to hold the company harmless from the alleged harm caused by the Company's officers and directors by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing. You can click or copy and paste the link below in a browser to join this action:
https://www.johnsonfistel.com/investigations/bioxcel-therapeutics-investigation
Recently a class action complaint was filed against the company. The BioXcel class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) BioXcel lacked adequate internal controls over protocol adherence and data integrity; (ii) as a result, BioXcel's principal investigator failed to adhere to the informed consent form approved by the Institutional Review Board; (iii) BioXcel's principal investigator failed to maintain adequate case histories for certain patients whose records were reviewed by the U.S. Food and Drug Administration ("FDA"); (iv) BioXcel's principal investigator fabricated email correspondence with a pharmacovigilance safety vendor that was then provided to the FDA; and (v) the above would negatively impact BioXcel's ability to obtain regulatory approval of BXCL501 for the treatment of agitation associated with dementia in patients with probable Alzheimer's disease.
*ImmunityBio, Inc. (NASDAQ: IBRX)*
Johnson Fistel, LLP is investigating potential claims on behalf of ImmunityBio, Inc. (NASDAQ: IBRX) against certain of its officers and directors.
If you are a current, long-term shareholder of ImmunityBio, continuously holding shares since May 23, 2022, you may have standing to hold the company harmless from the alleged harm caused by the Company's officers and directors by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing. You can click or copy and paste the link below in a browser to join this action:
https://www.johnsonfistel.com/investigations/immunitybio-inc
Recently a class action complaint was filed against the company. The filed complaint alleges that defendants made false statements and/or concealed that: (i) ImmunityBio conducted insufficient due diligence to discover, or else did discover and ignored, Good Manufacturing Practice ("GMP") deficiencies at its third-party contract manufacturing organizations ("CMOs") for the antibody cytokine fusion protein N-803, commercially referred to as "Anktiva"; (ii) one or more of the Company's third-party CMOs for Anktiva did in fact suffer from GMP deficiencies; (iii) the foregoing deficiencies was likely to cause the FDA to reject the Anktiva Biologics License Application ("BLA") in its present form; (iv) accordingly, the Company overstated the regulatory approval prospects for the Anktiva BLA; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
*About Johnson Fistel, LLP:*
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. Johnson Fistel seeks to recover losses incurred due to violations of federal securities laws. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, LLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
*Contact: *
Johnson Fistel, LLP
501 W. Broadway, Suite 800, San Diego, CA 92101
James Baker, Investor Relations or Frank J. Johnson, Esq., (619) 814-4471
jimb@johnsonfistel.com or fjohnson@johnsonfistel.com